Skip to main content

Ensysce Biosciences, Inc. (ENSC)

NASDAQ: ENSC · IEX Real-Time Price · USD
2.36
-0.01 (-0.42%)
After-hours:Oct 15, 2021 7:22 PM EDT
2.37
-0.11 (-4.44%)
At close: Oct 15, 4:00 PM
Market Cap57.49M
Revenue (ttm)1.94M
Net Income (ttm)-4.29M
Shares Out16.05M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume421,187
Open2.52
Previous Close2.48
Day's Range2.35 - 2.58
52-Week Range2.23 - 23.99
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About ENSC

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.

IndustryBiotechnology
Founded2003
Employees4
Stock ExchangeNASDAQ
Ticker SymbolENSC
Full Company Profile

Financial Performance

Financial Statements

News

Ensysce Biosciences Announces $15 Million Convertible Note Financing

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to...

2 weeks ago - GlobeNewsWire

Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid,...

Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, on September 7, 2021 Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, o...

1 month ago - GlobeNewsWire

Ensysce Biosciences Sets September 2021 Conference Schedule

SAN DIEGO, CA / ACCESSWIRE / August 31, 2021 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company with proprietary technology platform...

1 month ago - Accesswire

Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to ...

1 month ago - GlobeNewsWire

Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to ...

2 months ago - GlobeNewsWire

Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to ...

2 months ago - GlobeNewsWire

Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW) today announced that the Company will begin trading its common stock under ...

3 months ago - GlobeNewsWire

Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC: LACQ, LACQW) today announced that, in connection with the closing of its previously announced me...

3 months ago - GlobeNewsWire

Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination

NEW YORK, June 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("LACQ" or the "Company") (Nasdaq: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merge...

4 months ago - PRNewsWire

Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer

NEW YORK and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addictio...

7 months ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Le...

New York, New York--(Newsfile Corp. - February 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Leisure Acquisition Corp. ("Leisure ...

8 months ago - Newsfile Corp

SHAREHOLDER ALERT: WeissLaw LLP Investigates Leisure Acquisition Corp.

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leisure Acquisition Corp. ("Leisure" or ...

8 months ago - PRNewsWire

5 SPAC IPOs That Could Sooner Go To Zero

However, history confirms that many SPAC IPOs don't deliver returns on par with comparable companies that went public the traditional route. Additionally, not all SPACs find a company to partner with, m...

Other symbols:HYLNNKLASPCE
11 months ago - InvestorPlace

10 SPAC IPO Stocks to Buy As the Market Enters Bear Territory

As the markets continue further into bear-market territory, investors might want to consider some of these SPAC IPO stocks.

Other symbols:ACAMHYACRPAYSPCE
1 year ago - InvestorPlace